ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03602560 |
Recruitment Status :
Completed
First Posted : July 27, 2018
Results First Posted : May 31, 2022
Last Update Posted : August 2, 2022
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
A 52-week, placebo-controlled, randomized, Phase 3 study to evaluate the safety and efficacy of seladelpar in subjects with primary biliary cholangitis (PBC) and an inadequate response to or intolerance to ursodeoxycholic acid (UDCA)
The participants might enter the ongoing open-label safety study (NCT03301506) following this double-blind study.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Primary Biliary Cholangitis | Drug: seladelpar 5-10 mg Drug: seladelpar 10 mg Drug: Placebo | Phase 3 |
Primary:
- To evaluate the safety and effect on cholestasis of two seladelpar regimens (5 mg/day titrated to 10 mg/day and 10 mg/day) over 52 weeks of treatment compared to placebo
Key Secondary:
- To evaluate the effect of seladelpar on normalization of alkaline phosphatase (AP) levels
- To evaluate the effect of seladelpar on pruritus
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 265 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A 52-week, Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Safety and Efficacy of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) |
Actual Study Start Date : | October 1, 2018 |
Actual Primary Completion Date : | February 16, 2020 |
Actual Study Completion Date : | February 16, 2020 |
Arm | Intervention/treatment |
---|---|
Experimental: Seladelpar 5-10 mg |
Drug: seladelpar 5-10 mg
Seladelpar 5 mg for 6 months and then titrating up to 10 mg based on tolerability and response for remainder of double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects will continue the seladelpar dose (5 or 10 mg) received during the double-blinded study |
Experimental: Seladelpar 10 mg |
Drug: seladelpar 10 mg
Seladelpar 10 mg for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label safety study. Subjects will continue the seladelpar dose (10 mg) received during the double-blinded study |
Placebo Comparator: Placebo |
Drug: Placebo
One capsule daily for double-blind period. After completion of the 1-year double-blind period subjects will be offered the opportunity to enter an open label long term safety study. Subjects on placebo will be re-randomized to initiate seladelpar at 5 or 10 mg once daily |
- Percentage of Participants With Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% Reduction in ALP, and Total Bilirubin ≤ ULN) at Month 3 [ Time Frame: Month 3 ]
Percentage of Participants with Response to Composite Endpoint of ALP <1.67 × Upper Limit of Normal [ULN], ≥15% reduction in ALP, and total bilirubin ≤ ULN) at Month 3. The mITT analysis set included all randomized subjects who received at least one study drug dose.
The primary endpoint was analyzed using Cochran-Mantel-Haenszel (CMH) test adjusted for both randomization stratification variables (ALP level: <350 U/L and 2:350 U/L; pruritus NRS: <4 and 2:4). The CMH tests were performed for the comparison of 10 mg versus placebo and 5 mg/10 mg versus placebo separately.
- Percentage of Participants With Response Defined by Normalized Alkaline Phosphatase Levels at Month 3 [ Time Frame: Month 3 ]The response was defined by normalized ALP levels (ALP ≤1.0 × ULN) at endpoint. The mITT analysis set included all randomized subjects who received at least one study drug dose.
- Change From Baseline in Pruritus NRS for Subjects With Baseline NRS ≥4 at Month 3 [ Time Frame: Month 3 ]Pruritus Numerical Rating Scale (NRS) used to rate the intensity of the worst itching you experienced in the past 24 hours from no itching to worst possible itching by selecting a number from 0 to 10 on Itch Scale. Zero means no itching and 10 means worst imaginable itching. The analysis will be limited to those subjects in the mITT analysis set with a baseline NRS ≥ 4.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Must have given written informed consent (signed and dated) and any authorizations required by local law
- 18 to 75 years old (inclusive)
-
Male or female with a diagnosis of PBC, by at least two of the following criteria:
- History of AP above ULN for at least six months
- Positive anti-mitochondrial antibody (AMA) titers (>1/40 on immunofluorescence or M2 positive by enzyme linked immunosorbent assay [ELISA]) or positive PBC-specific antinuclear antibodies
- Documented liver biopsy result consistent with PBC
- On a stable and recommended dose of UDCA for the past twelve months OR intolerant to UDCA (last dose of UDCA > 3 months prior to Screening)
- AP ≥ 1.67 × ULN
- Females of reproductive potential must use at least one barrier contraceptive and a second effective birth control method during the study and for at least 90 days after the last dose. Male subjects who are sexually active with female partners of reproductive potential must use barrier contraception and their female partners must use a second effective birth control method during the study and for at least 90 days after the last dose
Exclusion Criteria:
- Previous exposure to seladelpar (MBX-8025)
- A medical condition, other than PBC, that in the investigator's opinion would preclude full participation in the study or confound its results (e.g., cancer)
- AST above 3 × ULN
- ALT above 3 × ULN
- Total bilirubin above 2.0 × ULN
- Advanced PBC as defined by the Rotterdam criteria (albumin below LLN AND total bilirubin above 1 × ULN)
- Creatine kinase (CK) above 1.0 × ULN
- eGFR below 60 mL/min/1.73 m2 (calculated by MDRD formula)
- International normalized ratio (INR) above 1.0 × ULN
- Platelet count below 100 × 103/µL
-
Presence of clinically significant hepatic decompensation, including:
- History of liver transplantation, current placement on liver transplantation list, or current MELD score ≥ 15
- Complications of portal hypertension, including known esophageal varices, history of variceal bleeds or related interventions (e.g., transjugular intrahepatic portosystemic shunt placement), relevant ascites, hepatic encephalopathy
- Cirrhosis with complications, including history or presence of spontaneous bacterial peritonitis
-
Other chronic liver diseases:
- Current features of auto-immune hepatitis as determined by the investigator based on immunoserology, liver biochemistry and histology
- Primary sclerosing cholangitis determined by presence of diagnostic cholangiographic findings
- History or clinical evidence of alcoholic liver disease
- History or clinical evidence of alpha-1-antitrypsin deficiency
- Biopsy confirmed nonalcoholic steatohepatitis
- History or evidence of Gilbert' Syndrome with elevated total bilirubin
- History or evidence of hemochromatosis
- Hepatitis B defined as presence of hepatitis B surface antigen (HBsAg)
- Hepatitis C defined as presence of HCV RNA
- Known history of HIV
- Evidence of significant alcohol consumption
- Evidence of drug abuse
- Subjects with inadequate response to obeticholic acid (OCA) or intolerance to OCA: OCA must be discontinued 30 days prior to Screening
- Use of colchicine, methotrexate, azathioprine, or long-term systemic corticosteroids (> 2 weeks) within two months prior to Screening
- Use of fibrates within 30 days prior to Screening
- Use of simvastatin within 7 days prior to Screening
- Use of an experimental or unapproved treatment for PBC within 30 days prior to Screening
- Use of experimental or unapproved immunosuppressant within 30 days prior to Screening
- Treatment with any other investigational therapy or device within 30 days or within five half-lives, whatever is longer, prior to Screening
- For females, pregnancy or breast-feeding
- Any other condition(s) that would compromise the safety of the subject or compromise the quality of the clinical study, as judged by the investigator
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03602560
Documents provided by CymaBay Therapeutics, Inc.:
Responsible Party: | CymaBay Therapeutics, Inc. |
ClinicalTrials.gov Identifier: | NCT03602560 |
Other Study ID Numbers: |
CB8025-31735 |
First Posted: | July 27, 2018 Key Record Dates |
Results First Posted: | May 31, 2022 |
Last Update Posted: | August 2, 2022 |
Last Verified: | July 2022 |
Studies a U.S. FDA-regulated Drug Product: | Yes |
Studies a U.S. FDA-regulated Device Product: | No |
PBC Primary Biliary Cholangitis (PBC) |
Cholangitis Liver Cirrhosis, Biliary Bile Duct Diseases Biliary Tract Diseases Digestive System Diseases Cholestasis, Intrahepatic Cholestasis Liver Diseases |
Liver Cirrhosis Fibrosis Pathologic Processes Seladelpar Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action Lipid Regulating Agents |